Viatris Inc. (VTRS)
| Market Cap | 8.93B |
| Revenue (ttm) | 14.74B |
| Net Income (ttm) | -634.20M |
| Shares Out | 1.19B |
| EPS (ttm) | -0.53 |
| PE Ratio | n/a |
| Forward PE | 3.39 |
| Dividend | $0.48 (6.42%) |
| Ex-Dividend Date | Mar 10, 2025 |
| Volume | 11,897,557 |
| Open | 7.59 |
| Previous Close | 7.63 |
| Day's Range | 7.40 - 7.66 |
| 52-Week Range | 6.85 - 13.55 |
| Beta | 0.91 |
| Analysts | Hold |
| Price Target | 10.50 (+40.37%) |
| Earnings Date | May 8, 2025 |
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for VTRS stock is "Hold." The 12-month stock price forecast is $10.5, which is an increase of 40.37% from the latest price.
News
Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer
PITTSBURGH , April 14, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer.
VTRS STOCK FRAUD: Did Viatris Inc. Commit Securities Fraud? Investors are Notified to Contact BFA Law by the June 3 Court Deadline (NASDAQ:VTRS)
NEW YORK, April 11, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ: VTRS) and certain of the Compa...
VTRS STOCK NOTICE: Viatris Inc. is being Sued for Fraud - Investors with Losses are Reminded to Contact BFA Law by June 3 Deadline
NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) and certain of the C...
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Viatris, Inc. (VTRS)
NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Western District of P...
VTRS FRAUD NOTICE: Viatris Inc. Investors with Losses may have been Affected by Fraud; Contact BFA Law by June 3 Court Deadline
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Viatris Inc. (NASDAQ:VTRS) and certain of t...
Viatris to pay up to $335 million to resolve opioid-related claims
Viatris said on Monday it would pay up to a maximum of $335 million over nine years as part of a nationwide settlement to resolve opioid-related claims against the drugmaker.
Viatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims
PITTSBURGH , April 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) (the "Company") today announced it has reached a nationwide settlement framework to resolve opioid-related claims by states, loca...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
VTRS Investors Have Opportunity to Join Viatris Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , April 3, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Viatris Inc. ("Viatr...
Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility – Hagens Berman
SAN FRANCISCO, April 01, 2025 (GLOBE NEWSWIRE) -- On February 27, 2025, investors saw the price of their shares of Viatris Inc. (NASDAQ: VTRS) tumble over 15% after the company disclosed an anticipate...
Viatris to Report First Quarter 2025 Financial Results on May 8, 2025
PITTSBURGH , March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m.
If you love dividend stocks, check out these 11 companies with room to boost their hefty payouts
If you want to generate income from your investment portfolio, you can easily spread your risk across a large group of stocks through mutual funds or exchange-traded funds, some of which in turn pay d...